- Trials with a EudraCT protocol (848)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (31)
848 result(s) found for: Neoadjuvant Chemotherapy.
Displaying page 1 of 43.
EudraCT Number: 2011-001856-12 | Sponsor Protocol Number: NT-12331-5 | Start Date*: 2011-08-11 |
Sponsor Name:The Motol University Hospital | ||
Full Title: Early assessment of effectivness of neoadjuvant chemotherapy for carcinoma of the esophagus and esophago-gastric junction using FDG-PET/CT. | ||
Medical condition: adenocarcinoma of the esophagus and esophago-gastric junction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002435-15 | Sponsor Protocol Number: FiHM003 | Start Date*: 2017-08-10 |
Sponsor Name:Fundación de Investigación HM Hospitales | ||
Full Title: Pilot study to assess physical exercise intervention in neoadjuvant treatment with nab-paclitaxel in patients with triple negative breast cancer | ||
Medical condition: Supervised exercise regimen given during neoadjuvant chemotherapy for triple negative breast cancer patients. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004796-12 | Sponsor Protocol Number: AIO-PAK-0113 | Start Date*: 2014-07-02 | |||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||
Full Title: Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer | |||||||||||||
Medical condition: Locally advanced pancreatic cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002833-39 | Sponsor Protocol Number: CHUBX2017/52 | Start Date*: 2018-12-12 |
Sponsor Name:CHU DE BORDEAUX | ||
Full Title: A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment for locally recurrent rectal cancer (GRECCAR – PRODIGE ... | ||
Medical condition: Recurrent rectal cancer after local excision | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002469-37 | Sponsor Protocol Number: CA209-7FL | Start Date*: 2020-01-29 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With Hi... | |||||||||||||||||||||||
Medical condition: Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) DE (Completed) CZ (Completed) FR (Completed) PL (Completed) NL (Completed) BE (Completed) DK (Completed) FI (Completed) IE (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing) RO (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003808-39 | Sponsor Protocol Number: MK-3475-866 | Start Date*: 2019-07-01 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible ... | |||||||||||||
Medical condition: Muscle Invasive Bladder Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Ongoing) BE (Trial now transitioned) HU (Ongoing) ES (Ongoing) PL (Trial now transitioned) FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003104-12 | Sponsor Protocol Number: M19VLC | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:NKI-AVL | |||||||||||||
Full Title: Treatment of locally advanced VULvar CArcinoma in a Neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy | |||||||||||||
Medical condition: vulvar carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000658-39 | Sponsor Protocol Number: AkupresSNP | Start Date*: 2016-07-11 |
Sponsor Name:Region Jönköpings län | ||
Full Title: Randomized multicenter study of Acupressure combined with personalized antiemetics based on genetic variations (SNPs) in women undergoing neoadjuvant or adjuvant chemotherapy EC / FEC against breas... | ||
Medical condition: Nausea in conjuction with neoadjuvant or adjuvant chemotherapy (FEC/EC) for patients with breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003565-10 | Sponsor Protocol Number: SAKK06/17 | Start Date*: 2018-12-03 | |||||||||||
Sponsor Name:Swiss Group for Clinical Cancer Research | |||||||||||||
Full Title: Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II Trial. | |||||||||||||
Medical condition: muscle invasive urothelial cancer (MIUC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004692-31 | Sponsor Protocol Number: CA017-078 | Start Date*: 2019-03-18 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab... | ||||||||||||||||||
Medical condition: Bladder Cancer Muscle-Invasive Bladder Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Temporarily Halted) AT (Ongoing) BE (Ongoing) NO (Ongoing) NL (Ongoing) FI (Ongoing) GR (Ongoing) ES (Ongoing) PT (Ongoing) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003503-39 | Sponsor Protocol Number: 2006-6 | Start Date*: 2006-09-08 |
Sponsor Name:Jens Benn Sorensen, Dept. oncology, Finsen Centre/National University Hospital | ||
Full Title: Multicenter fase III undersøgelse af effekten af præoperativ (neoadjuverende) kemoterapi inden operation med efterfølgende adjuverende kemoterapi ved operabel NSCLC stadie IB, IIA; IIB, og IIIA/T3. | ||
Medical condition: operable NSCLC. Pts are randomized to receive or not receive two courses of neoadjuvant chemotherapy before surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001199-23 | Sponsor Protocol Number: ICR-CTSU/2014/10048 | Start Date*: 2016-10-11 | |||||||||||
Sponsor Name:The Institute of Cancer Research | |||||||||||||
Full Title: InPACT - International Penile Advanced Cancer Trial (International Rare Cancer Initiative) | |||||||||||||
Medical condition: Locally advanced squamous carcinoma of the penis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005850-27 | Sponsor Protocol Number: NAPEER | Start Date*: 2022-05-31 |
Sponsor Name:Oslo University Hospital | ||
Full Title: An open label phase II trial in hormone receptor positive breast cancer patients randomized to neoadjuvant chamotherapy with or without bevacizumab (if ViRP signature positive) followed by endocrin... | ||
Medical condition: Hormone receptor positive primary breast cancer with tumor measuring > 2.0 cm that will be recommended chemotherapy and antihormone therapy according to the treatment guidelines for curative breast... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002520-17 | Sponsor Protocol Number: GOGER-01 | Start Date*: 2013-11-27 | |||||||||||||||||||||||||||||||
Sponsor Name:AOU di Bologna, Policlinico S.Orsola-Malpighi | |||||||||||||||||||||||||||||||||
Full Title: Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma | |||||||||||||||||||||||||||||||||
Medical condition: neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004045-16 | Sponsor Protocol Number: ET18-272 | Start Date*: 2019-03-14 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bo... | ||
Medical condition: Patients with bone sarcomas other than Ewing sarcoma or chondrosarcoma or chordoma, who have no residual disease after neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004123-19 | Sponsor Protocol Number: MUN-391-LOR-0050-I | Start Date*: 2006-01-24 |
Sponsor Name:Klinikum rechts der Isar der Technischen Universitaet Muenchen | ||
Full Title: Metabolic Response Evaluation for an Individualization of Neoadjuvant Chemo- and Radiotherapy in Esophageal Adenocarcinoma | ||
Medical condition: This study will test an optimized therapy for patients with chemotherapy-resistent locally advanced adenocarcinomas at the gastro-esophageal junction. According to the protocol, patients should re... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004526-41 | Sponsor Protocol Number: ONCOGHdC2015-02 | Start Date*: 2017-03-23 |
Sponsor Name:Grand hôpital de Charleroi | ||
Full Title: A PHASE Ib/II STUDY TO EVALUATE SAFETY AND EFFICACY OF ATEZOLIZUMAB COMBINED WITH RADIO-CHEMOTHERAPY IN A PREOPERATIVE SETTING FOR PATIENTS WITH LOCALIZED RECTAL CANCER (R-IMMUNE) | ||
Medical condition: Rectum cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015238-31 | Sponsor Protocol Number: M09TNM | Start Date*: 2009-12-16 | |||||||||||
Sponsor Name:NKI-AVL | |||||||||||||
Full Title: RANDOMIZED PHASE II/III STUDY OF INDIVIDUALIZED NEOADJUVANT CHEMOTHERAPY IN ‘TRIPLE-NEGATIVE’ BREAST TUMORS | |||||||||||||
Medical condition: Triple negative breast cancer treated with neoadjuvant chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012019-17 | Sponsor Protocol Number: BO22280 | Start Date*: 2009-09-02 | |||||||||||
Sponsor Name:F. Hoffmann - La Roche Ltd | |||||||||||||
Full Title: A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemother... | |||||||||||||
Medical condition: Locally advanced, inflammatory or early stage HER2-positive breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) GB (Completed) PT (Completed) GR (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001850-24 | Sponsor Protocol Number: ABCSG_P02 | Start Date*: 2012-08-10 |
Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group) | ||
Full Title: A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer | ||
Medical condition: locally advanced, primarily inoperable pancreatic carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.